InterAx developed a unique drug discovery platform integrating biochemistry, cellular pathways mathematical modelling and AI to decode the cellular communication language. This novel approach enables the rapid and precise identification of differentiated effective and safe candidates.
Products, services, technology
Oral daily GLP-1R agonist (IAX30-series) for T2D and weight loss. It offers an optimal profile to reduce nausea, it enables prevention of T2D progression and holds potential for combination with a GIP-R antagonist (IAX35-series) to maximize weight-loss efficacy with improved tolerability.
- http://www.interaxbiotech.com
- Send an email
- Dr. Aurélien Rizk